🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

11+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 11 of 11 recruiting trials for “Chronic myelomonocytic leukemia”

EARLY_Phase 1RecruitingNCT07071155 ↗

Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia

👨‍⚕️ Tania Jain, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins📍 1 site📅 Started Mar 2026View details ↗
Phase 2RecruitingNCT06815003 ↗

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

👨‍⚕️ Monzr M. Al Malki, City of Hope Medical Center📍 1 site📅 Started Apr 2025View details ↗
Phase 2RecruitingNCT06597734 ↗

A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

👨‍⚕️ Kelly Chien, MD, M.D. Anderson Cancer Center📍 1 site📅 Started Jan 2025View details ↗
Phase 1RecruitingNCT06543381 ↗

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

👨‍⚕️ Amandeep Salhotra, MD, City of Hope Medical Center📍 2 sites📅 Started Jan 2025View details ↗
Phase 3RecruitingNCT06647862 ↗

IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

👨‍⚕️ zhijian xiao, PHD, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College📍 43 sites📅 Started Nov 2024View details ↗
Phase 1RecruitingNCT06218628 ↗

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

👨‍⚕️ Peter Abdelmessieh, DO, MSc, Fox Chase Cancer Center📍 1 site📅 Started Apr 2024View details ↗
Phase 1RecruitingNCT05488548 ↗

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

👨‍⚕️ Judy Chiao, MD, Epigenetix, Inc.📍 6 sites📅 Started Dec 2022View details ↗
Phase 2RecruitingNCT04239157 ↗

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

👨‍⚕️ Guillermo Garcia-Manero, M.D. Anderson Cancer Center📍 1 site📅 Started Aug 2020View details ↗
Phase 1, PHASE2RecruitingNCT04493138 ↗

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

👨‍⚕️ Guillermo M Bravo, M.D. Anderson Cancer Center📍 1 site📅 Started Jul 2020View details ↗
Phase 1, PHASE2RecruitingNCT04140487 ↗

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

👨‍⚕️ Nicholas Short, M.D. Anderson Cancer Center📍 1 site📅 Started Dec 2019View details ↗
Phase 1RecruitingNCT03896269 ↗

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

👨‍⚕️ Guillermo M Bravo, M.D. Anderson Cancer Center📍 1 site📅 Started May 2019View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →